

(FILE 'HOME' ENTERED AT 08:45:31 ON 06 JAN 2005)

FILE 'REGISTRY' ENTERED AT 08:45:39 ON 06 JAN 2005

L1 1 S OLOPATADINE/CN

FILE 'USPATFULL' ENTERED AT 08:46:19 ON 06 JAN 2005

L2 1 S US5641805/PN
L3 0 S L2 AND OLOPATADINE
L4 1 S L2 AND L1
L5 0 S L4 AND (ALLERGIC RHINITIS)
L6 0 S L2 AND (NASAL OR INTRANASAL)

FILE 'USPATFULL' ENTERED AT 08:48:38 ON 06 JAN 2005

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, ...' ENTERED AT 08:48:42 ON 06 JAN 2005

L7 640 S L1
L8 96 S L7 AND (NASAL OR INTRANASAL OR INTRANASALLY)
L9 44 S L8 AND PD<2003
L10 34 DUP REM L9 (10 DUPLICATES REMOVED)
L11 16 S L10 AND (RHINITIS)
L12 16 S L11 AND ALLERGIC
L13 16 S L12 AND (ALLERGIC (W) RHINITIS)
L14 0 S L13 AND (PH OR VISCOSITY OR PARTICLE OR SIZE)
L15 449 S (OLOPATADINE OR PATANOL)/AB
L16 52 S L15 AND (INTRANASAL OR NOSE OR NASAL)/AB
L17 24 S L16 AND PD<2003
L18 6 DUP REM L17 (18 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 09:10:05 ON 06 JAN 2005

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, ...' ENTERED AT 09:15:02 ON 06 JAN 2005

L19 919 S RHINOCONJUNCTIVITIS (P) (ALLERGIC (W) RHINITIS)
L20 463 DUP REM L19 (456 DUPLICATES REMOVED)
L21 196 S L20 AND PD<2003
L22 18 S (RHINOCONJUNCTIVITIS (P) (ALLERGIC (W) RHINITIS) (P) (DEFINED

=>

L2 ANSWER 1 OF 1 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on STN
AN 1999:19365 ADISCTI
DN 800752408
TI **Direct expenditures** for the **treatment** of
allergic **rhinoconjunctivitis** in **1996**, including the
contributions of related **airway illnesses**.
ADIS TITLE: Allergic rhinitis: **treatment**.
Combined with allergic conjunctivitis
Cost analysis in the US in **1996**.
AU Ray N F; Baraniuk J N; Thamer M; Rinehart C S; Gergen P J; et al.
CS Medical Technology and Practice Patterns Institute, Washington, District
of Columbia, USA.
SO Journal of Allergy and Clinical Immunology (Mar 1, 1999), Vol. 103, pp.
401-407
DT Study
RE Obstructive Airways Disease| PharmacoEconomics
FS Summary
LA English
WC 390
TX Purpose:
Estimated costs of allergic rhinitis in the US have increased from \$US1.2
to \$US1.8 billion in the 1990-1994 period. Studies to date have yet to
estimate the costs of treating allergic rhinitis as a comorbid disorder
associated with an alternative primary airway disorder.
This study determined the direct costs associated with allergic rhinitis
combined with allergic conjunctivitis (allergic rhinoconjunctivitis) for
the US in 1996. Costs were also determined for various other primary
airway disorders in which allergic rhinoconjunctivitis could be considered
a comorbid condition.

TX Author Comments:
`[T]he economic burden of AR/AC [allergic rhinoconjunctivitis] in the
United States is substantial and disproportionate to the number of
affected persons. The direct cost of care for AR/AC (\$1.9 billion) was
less than that for the comorbid disorders, such as asthma (\$6.7 billion),
chronic otitis media (\$4.9 billion) and sinusitis (\$3.4 billion), but the
overall cost attributable to AR/AC was estimated at \$5.93 billion. These
costs are likely to escalate given the rising prevalence of atopic
diseases over the past several decades. Earlier evaluation and treatment
of the allergic component may substantially reduce long term-expenditures
by arresting the progression from rhinitis to disorders with greater
morbidity and cost.'

TX Study Details:
Methodology: a Delphi panel identified the costs of the proportion of
visits for other primary airway disorders attributable to allergic
rhinoconjunctivitis. A national healthcare survey was used to obtain costs
associated with inpatient (facility expenses and physician visits) and
outpatient care (including hospital, physician, emergency department and
prescriptions). Costs were also determined according to age (< 12 and > 13
years of age) and were expressed in 1996 values.
Companies: Janssen

TX Results:

Primary airway disorders	Total direct medical costs attributable to allergic rhinoconjunctivitis in the USA in 1996 (\$US; million)
Allergic rhinoconjunctivitis	1863.4
Chronic otitis media/ eustachian tube disorders	1483.5
Sinusitis	1017.3

Asthma	1006.7
Acute upper respiratory infection	211.8
Pharyngitis/tonsillitis	165.7
Other conjunctivitis	88.0
Chronic rhinitis	62.3
Rhinorrhoea	32.0
Total	5930.8

38 and 62% of the total expenditures attributable to allergic rhinoconjunctivitis were for patients < 12 and > 13 years of age, respectively. Chronic otitis media and eustachian tube disorders, allergic rhinoconjunctivitis and asthma were responsible for 52.1, 15.8 and 11.3% of costs in patients aged < 12, respectively. For patients > 13 years, allergic rhinoconjunctivitis, sinusitis and asthma contributed 41.0, 22.9 and 20.4% of total direct costs, respectively.

CT Disease Descriptors: Allergic rhinitis, treatment; Allergy, treatment; Ear nose and throat disorders, treatment; Immunological disorders, treatment; Inflammation, treatment; Nose disorders, treatment; Respiratory tract disorders, treatment; Rhinitis, treatment; Rhinoconjunctivitis, treatment; Conjunctival disorders, treatment; Conjunctivitis, treatment; Eye disorders, treatment; Ocular inflammation, treatment

CT Pharmacoeconomic Descriptors: Cost analysis; Health economics; Pharmacoeconomics

CT Other Descriptors: Children

=>